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Fulvestrant (Faslodex™) is a pure antiestrogen that is effective in treating estrogen receptor-(ER) positive breast
cancer tumors that are resistant to selective estrogen receptor modulators such as tamoxifen. Clinical trials
investigating the utility of adding fulvestrant to other therapeutics have not been shown to affect cytochrome
P450-mediated metabolism. Effects on phase II metabolism and drug resistance have not been explored. This study
demonstrates that fulvestrant up regulates the expression of UDP glucuronosyltransferase 1A4 (UGT1A4) >2.5-
and >3.5-fold in MCF7 and HepG2 cells, respectively. Up regulation occurred in a time- and concentration-dependent
manner, and was inhibited by siRNA silencing of ERα. Fulvestrant also up regulates multidrug resistance-associated
proteins (MRPs). There was an up regulation of MRP2 (1.5- and 3.5-fold), and MRP3 (5.5- and 4.5-fold) in MCF7 and
HepG2 cell lines, respectively, and an up regulation of MRP1 (4-fold) in MCF7 cells. UGT1A4 mRNA up regulation was
significantly correlated with UGT1A4 protein expression, anastrozole glucuronidation, ERα mRNA expression and MRP
mRNA expression, but not with ERα protein expression. Genetic variants in the UGT1A4 promoter (−163A, -217G
and -219T) reduced the basal activity of UGT1A4 by 40-60%. In silico analysis indicated that transcription
factor c-Myb binding capacity may be affected by these variations. Luciferase activity assays demonstrate that silencing
c-Myb abolished UGT1A4 up regulation by fulvestrant in promoters with the common genotype (−163G, -217 T
and -219C) in MCF7 cells. These data indicate that fulvestrant can influence the disposition of other UGT1A4 substrates.
These findings suggest a clinically significant role for UGT1A4 and MRPs in drug efficacy.
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Fulvestrant (Faslodex™; ICI 182,780) belongs to a novel class
of endocrine agents for the treatment of breast cancer
(Howell et al. 2000; Osborne et al. 2004). Fulvestrant is a
pure antiestrogen which is effective in treating estrogen re-
ceptor (ER) positive tumors that are resistant to selective
estrogen receptor modulators (SERMs) such as tamoxifen
This compound differs significantly from tamoxifen in its
mode of action, which is through promoting the rapid deg-
radation of the ER. Fulvestrant shows no estrogen agonist
activity, and thus has been regarded as an important im-
provement in breast cancer therapy (Morris and Wakeling* Correspondence: sakadlubar@uams.edu
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that co-administration of fulvestrant with other therapeu-
tics may be beneficial, and clinical trials investigating this
are being conducted (Group 2004; AstraZeneca 2012).
However, the effect of co-administration on phase II drug
metabolism and drug disposition has not yet been reported.
The phase II biotransformation system comprises an
array of enzymes that incorporate a hydrophilic group into
hydrophobic molecules, thereby increasing solubility and
potentially decreasing the toxicity of the original target. Al-
tered rates of metabolism can affect systemic availability
and elimination half-life of xenobiotics. This can affect tox-
icity or therapeutic effect, and may result in undesirable
drug-drug interactions. A better understanding of simultan-
eous regulation of metabolism and disposition may help
prevent these undesirable effects.an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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P450 enzymes (CYPs) and phase II enzymes like sulfo-
transferases (SULTs) and UDP-glucuronosyltransferases
(UGTs). Fulvestrant has been shown to be glucuronidated
by human recombinant UGT1A1, UGT1A3, UGT1A4
and UGT1A8 enzymes. Kinetic analysis has revealed that
UGT1A4 displays the highest affinity for fulvestrant, and
that UGT1A3 and UGT1A4 display the highest catalytic
efficiency for fulvestrant glucuronidation (Chouinard et al.
2006; Starlard-Davenport et al. 2010).
Previous studies from this laboratory report that
genetic variations in UGT1A4 have a potential role in
inter-individual variability in anastrozole glucuronidation
(Edavana et al. 2013). These findings indicate that alter-
ations in UGT1A4 may significantly affect the glucuro-
nidation rates of fulvestrant. Thus variations may also
affect metabolism and disposition of drugs that are co-
administered with fulvestrant and which are substrates
for UGT1A4.
Drug disposition can be affected not only by factors
such as metabolic genes, but also transporter proteins
(Bock et al. 2000; Catania et al. 2004). Multidrug
resistance-associated proteins (MRPs) are a family of
ATP-dependent transporters that exhibit elevated ex-
pression levels in tumor cells. MRPs are preferentially
localized in the apical membrane of hepatocytes, renal
tubular cells and enterocytes (Catania et al. 2004). They
are involved in the secretion of a large number of conju-
gated compounds, and most MRP substrates are conju-
gated derivatives of endogenous compounds, drugs and
carcinogens (Keppler et al. 1997). Thus, MRPs may act
coordinately with phase II enzymes to eliminate these
compounds from the body. In the present study, the ef-
fects of fulvestrant on phase II metabolism regulation,
drug disposition and interactions with other therapeutics
are explored in breast cancer and liver cancer cell lines.
Materials and methods
Chemicals and reagents
Fulvestrant was provided by AstraZeneca Pharmaceuticals
(Macclesfield, Cheshire, UK). Anastrozole (2,2′-[5-(1H-1,2,4-
triazol-1-ylmethyl)-1,3-phenylene]bis (2-methylpropaneni-
trile) was obtained from Toronto Research Chemicals, Inc.
(Toronto, Canada). Alamethicin and UDP glucuronic acid
(UDPGA) were purchased from Sigma-Aldrich (St. Louis,
MO). Baculovirus-expressed human UGT1A4 was pur-
chased from BD Gentest Corp. (Woburn, MA). ERα siRNA
(h), c-Myb siRNA (h), ERα, c-Myb and UGT1A4 primary
and secondary antibodies were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Actin primary anti-
body was purchased from Sigma-Aldrich (St. Louis, MO)
Chemiluminescence reagents were obtained from GE
Healthcare (Piscataway, NJ). All other reagents were of
HPLC grade or of the highest grade commercially available.Cell culture
MCF7 cells from American Type Culture Collection
were maintained in RPMI 1640 supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, 6 ng of bovine
insulin/ml, 100 units of penicillin/ml, 100 μg of strepto-
mycin/ml, and 1% minimal essential medium nonessen-
tial amino acids. HepG2 cells (a kind gift from Yevgeniy
Apostolov, UAMS, AR) were cultured in complete
Dulbecco’s modified Eagle’s medium (MediaTech, Inc.,
Manassas, VA) supplemented with 10% fetal bovine serum
(Gemini, Woodland, CA), 2 mM L-glutamine, 100 units
of penicillin/ml, 100 μg of streptomycin/ml, and 1%
minimal essential medium nonessential amino acids. The
media were changed 3 days before each experiment to
estrogen-free media, i.e. complete Dulbecco’s modified
Eagle’s medium containing charcoal/dextran-stripped
fetal bovine serum (Gemini) and no phenol red.
Transfection of ERα and c-Myb siRNA
ERα and c-Myb siRNAs were transfected into cells ac-
cording to manufacturer’s protocol. The final concentra-
tion of inhibitor was 100 nM. After 48 h, cells were
harvested, total RNA was isolated, and ERα and c-Myb
expressions were measured by RT-PCR according to
manufacturer’s protocol (see below).
Quantitative real-time PCR
Total RNA was isolated using TRIzol (Invitrogen, Carls-
bad, CA), and was used as a template for cDNA synthe-
sis with Superscript II (Invitrogen, Grand Island, NY).
Quantitative RT-PCR was performed using a Prism
7900HT Sequence Detection System and SYBR Green
PCR Master Mix (Applied Biosystems, Foster City, CA).
Gene specific primers, annealing temperature and cycle
numbers for UGT1A4, ERα, MRP1, MRP2 and MRP3
have been described previously (Edavana et al. 2013; Ros
et al. 2003; Walton et al. 2009). The dissociation curves
for each reaction were examined to ensure amplification
of a single PCR product in the reaction. The -fold
change in mRNA levels was determined after normaliz-
ing the gene expression levels to those of β-actin (2-ΔΔCt
method) as described previously (Schmittgen and Livak
2008). Taqman gene expression assay (ABI, Foster city,
CA) was performed to assess c-Myb expression.
Transient transfection of UGT1A4 promoter constructs
and luciferase activity assay
A UGT1A4 promoter construct of 1.5 kb was inserted
upstream of the luciferase reporter gene in the pLightS-
witch_Prom vector (SwitchGear Genomics, Menlo Park,
CA). Variant alleles were generated with the Quik-
Change® Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA). Transient transfections of reference and vari-
ant promoter constructs (100 ng) were performed
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(Promega, Sunnyvale, CA). After 24 hrs cells were
treated either with fulvestrant (10 nM) or ethanol (ve-
hicle, 0.1%) for 48 hours. Luciferase activity was assessed
with the LightSwitch Luciferase assay system (Switch-
Gear Genomics) following the manufacturer’s protocol.
Results were analyzed by normalizing luciferase in trans-
fected cells to cells transfected with the empty pLightS-
witch_Prom vector. To determine the effect of
transcription factor c-Myb on UGT1A4 promoter ex-
pression, MCF7 cells transfected with the variant pro-
moter construct were treated with c-Myb siRNA before
fulvestrant treatment, and luciferase activity was
assessed.
Preparation of cytosol microsomes from cell lines
Solubilized microsomal protein was prepared as de-
scribed previously (Sirois et al. 1992; Muller-Decker
et al. 1995) with minor modification. Briefly, subconflu-
ent growth-arrested cells were homogenized on ice in
Tris-EDTA-diethyldithiocarbamic (TED) buffer [50 mM
Tris HCI (pH 8.0), 10 mM EDTA, and 1 mM diethyl-
dithiocarbamic acid] containing 2 mM octyl glucoside.
Cells were then centrifuged at 100,000 × g for 1 h at
4°C. The crude pellets were sonicated in TED sonication
buffer [20 msi; Tris-HCI (pH 8.0), 50 mM EDTA, and
0.1 mM diethyldithiocarbamic acid] containing 45 mM octyl
glucoside. The sonicates were centrifuged at 13,000 × g at
4°C, and the recovered supernatants containing the cyto-
solic microsomes were stored at −80°C until the assays
were performed.
Western blot
Cell lysates were separated by 12% SDS-polyacrylamide gel
electrophoresis. Proteins were transferred to a polyvinyli-
dene fluoride membrane and probed with anti-ERα, anti-c-
Myb and anti-UGT1A4 antibodies according to manufac-
turer’s protocol. Membranes were then incubated with
secondary antibody for 1 h before chemiluminescence
detection using SuperSignal West Femto Maximum Sensi-
tivity Substrate (Pierce, Rockford, IL). Actin was detected as
a loading control. Images were collected and analyzed using
the FluorChem™ SP imager with Alpha Ease FC
(FluorChem™ SP) software (San Leandro, CA).
In silico SNP analysis
The in silico program, is-rSNP, was utilized to explore
binding capacity changes in the promoter containing
variant sequences. The program utilizes JASPAR and
TRANSFAC to access the position weight matrix, and
uses this and a “sliding window approach” to create
scores and p-values that relate to transcription factor
binding capacity (Macintyre et al. 2010).Glucuronidation of anastrozole using microsomes isolated
from MCF7 and HepG2 cell lines
The glucuronidation of anastrozole was measured in mi-
crosomes prepared from MCF7 and HepG2 cell lines.
Enzymatic assays were performed according to standard
procedure described previously (Benoit-Biancamano
et al. 2009; Kamdem et al. 2010).Statistical analysis
Student’s t-tests were used to compare baseline and
treatment measurements within a group. Pearson’s cor-
relation coefficients were used to describe the linear as-
sociation between variables. All data from samples were
expressed as mean ± SEM. Statistical significance was
set at p < 0.05.Results
Induction of UGT1A4 expression and activity by
fulvestrant
To examine the effect of fulvestrant on the expression of
UGT1A4, ERα + MCF7 and HepG2 cells were used.
When concentration studies were performed, both cell
lines showed strong sensitivity towards 10 nM fulves-
trant. Cells were pre-treated with 1 nM fulvestrant for
30 days before experiments to decrease sensitivity and
increase longevity during subsequent fulvestrant treat-
ment. Cells were treated with different concentrations
(0, 5, 10, 20, 30, and 50 nM) of fulvestrant for 48 hours.
UGT1A4 was up regulated by fulvestrant treatment, and
the expression of UGT1A4 essentially plateaus at con-
centrations higher than 10 nM (Figure 1a). After treat-
ment with 10 nM fulvestrant, cells were harvested at
different time points (0, 24, 48, 72 and 96 hrs) and
mRNA levels were determined by qRT-PCR. Treatment
with fulvestrant up regulated UGT1A4 in a time-
dependent manner. Endogenous mRNA expression
levels of UGT1A4 peaked at 72 hours (>2.5-fold) in
MCF7 cells, and at 48 hours (>3.5-fold) in HepG2 cells
(Figure 1b). To determine if the regulation of UGT1A4
is mediated by the ER, siRNA silencing of ERα was per-
formed before repeating these experiments, which abol-
ished UGT1A4 up regulation upon fulvestrant treatment
(Figure 1a and b).
UGT1A4 protein levels were measured by Western
blot and anastrozole glucuronidation activities were
measured by mass spectrometry in MCF7 and HepG2
cells with and without ERα siRNA transfection before
treatment. Treatments were with 10 nM fulvestrant, and
data was collected over several time points. UGT1A4
mRNA was correlated with UGT1A4 protein expression
(r = 0.969 (MCF7) and 0.999 (HepG2), p < 0.01 (both))
and anastrozole glucuronidation activity (r = 0.875, p <
0.05 (MCF7), r = 0.961, p < 0.01 (HepG2); Table 1).
a b
Figure 1 Up regulation of UGT1A4 mRNA expression in MCF7 and HepG2 cell lines treated with fulvestrant. (a) MCF7 and HepG2 cells ±
transfection with ERα siRNA were treated with various concentrations of fulvestrant before UGT1A4 gene expression was measured. All data was
normalized to β-actin. (b) MCF7 and HepG2 cells were transfected as in (A), and then all were treated with 10 nM fulvestrant and analyzed for
UGT1A4 expression at various time points.
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protein levels
To confirm that UGT1A4 expression was partially medi-
ated through the ER pathway, ERα mRNA and protein
expression levels were measured and correlated to
UGT1A4 mRNA expression levels. (Figure 2a and b)
UGT1A4 mRNA expression levels correlated with ERα
mRNA (r = 0.915, p < 0.05 for MCF; r = 0.923, p < 0.01
for HepG2), but not with ERα protein levels (r = 0.760,
p > 0.05 for MCF7; r = 0.753, p > 0.05 for HepG2) in both
cell lines (Table 1). These results indicate that fulvestrant
induces UGT1A4 expression at least partially through an
ERα-mediated mechanism.
Transcriptional activation of UGT1A4 by fulvestrant
To study the mechanism of regulation of UGT1A4 by
fulvestrant, transcriptional activity modulation by the
UGT1A4 promoter was assessed by transient transfec-
tions in MCF7 and HepG2 cell lines. Each cell line wasTable 1 Correlation of UGT1A4, MRP and ERα in HepG2
and MCf7 Cell lines: Correlation analysis of MCF7/HepG2
UGT1A4 mRNA expression level with its own UGT1A4
protein, Anastrozole glucuronidation, ERα mRNA, ERα









MCF7/HepG2 ERα-mRNA 0.915* 0.923**
MCF7/HepG2 ERα-protein 0.760* 0.753
MCF7/HepG2 MRP1 0.972** NA
MCF7/HepG2 MRP2 0.906* 0.948**
MCF7/HepG2 MRP3 0.983** 0.967**
**p < 0.01; *p < 0.05.transfected with either pLightSwitch-UGT1A4 or the
empty pLightSwitch_Prom vector. The transfected cells
were then treated either with fulvestrant or with the
ethanol vehicle, and luciferase activities were deter-
mined. Upon treatment with fulvestrant, MCF7 and
HepG2 cells transfected with pLightSwitch_UGT1A4 ex-
hibited >5-fold (p < 0.01) increase in luciferase activity
compared with empty promoter-treated cells (Figure 3).
According to previous reports by this lab, UGT1A4
promoter SNPs -163G > A, -217 T > G and -219C > T
have been associated with inter-individual variability in
enzymatic activity in human liver microsomes (Edavana
et al. 2013). In this study, similar results were seen
with fulvestrant treatment. The -163G > A variant or
the -219C > T variant in either or both alleles reduced
the basal luciferase activity by 40-50% (p < 0.01) and
30-40% (p ≤ 0.01) respectively in MCF7 and HepG2cells.
The -217 T > G variant in either or both alleles in-
creased the basal luciferase expression by 20-50% (p ≤ 0.01)
in both cell lines. The complete variant haplotype
(−163A, -217G and -219 T) reduced control luciferase
activity by 40-60% (p ≤ 0.01) from the reference pro-
moter in both cell lines (Figure 4).
In silico analysis using is-rSNP revealed that the
UGT1A4 -163 variant is associated with changes in the
c-Myb transcription factor binding site. MCF7 expresses
c-Myb, but HepG2 cells do not, therefore c-Myb tran-
scription factor silencing was performed only in MCF7
cells. In the presence of c-Myb, fulvestrant up-regulated
the luciferase activity of UGT1A4 promoter expressing
the common alleles 1.5-fold more than the promoter
with the variant alleles (p < 0.01, Figure 5). When c-Myb
was silenced, no fulvestrant-induced up-regulation in lu-
ciferase activity was detected (Figure 5). c-Myb appears
to affect fulvestrant-induced UGT1A4 promoter activity
in the promoter with common alleles, but variation in
a b
Figure 2 Correlation of UGT1A4 mRNA with ER expression. Correlation of UGT1A4 mRNA with ER protein (a) and with ER mRNA (b) in
HepG2 and MCF7 cell lines treated with fulvestrant. Cells were treated with 10 nM fulvestrant. UGT1A4 and ER mRNA and protein expressions
were measured at various time points.
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c-Myb binding.
Induction of multidrug resistance-associated protein by
fulvestrant
MRPs have been characterized as apical glucuronide ex-
port pumps. (Cui et al. 1999; Munzel et al. 1999). In
order to investigate regulation by fulvestrant, MRP ex-
pression levels were analyzed in MCF7 and HepG2 cell
lines. Cells were treated with 10nM fulvestrant, and
MRP1, MRP2 and MRP3 expression levels were mea-
sured at various time points. Gene expression was up-
regulated for MRP1, MRP2 and MRP3, and expression
peaked at 48 hours in both cell lines. Thus, MRPs and
UGT1A4 were coordinately induced by fulvestrant.
UGT1A4 mRNA levels correlate with MRP1 (r = 0.972;
p < 0.05), MRP2 (r = 0.906; p<0.01) and MRP3 (r = 0.983;Figure 3 UGT1A4 luciferase activity measured in MCF7 and HepG2 ce
reference promoter. Then treated with 10 mM fulvestrant and luciferase acp < 0.05) expression levels in MCF7 cells. UGT1A4
mRNA levels correlate with MRP2 (r = 0.948; p < 0.05)
and MRP3 (r = 0.967; p < 0.05) expression in HepG2 cells
(MRP1is not expressed in HepG2; Table 1).
Discussion
Fulvestrant is effective in treating tamoxifen resistant
ER-positive metastatic breast cancer tumors (Robertson
et al. 2001). Recently, clinical trials investigating the util-
ity of adding fulvestrant to other therapeutics have not
been shown to affect cytochrome P450-mediated metab-
olism of either of the applied drugs (Robertson et al.
2004; Hiscox et al. 2009). Effects of co-administration on
phase II metabolism and drug transporter genes, how-
ever, have not been explored. Metabolic biotransform-
ation of endogenous and exogenous compounds renders
lipophilic molecules more soluble in water, allowingll lines. Cells were transfected either with empty vector or UGT1A4
tivity was measured *p value < 0.01.
a b
Figure 4 Promoter variant luciferase activity in various cell lines. Promoter variant luciferase activity measured in MCF7 (a) and HepG2 (b)
cells. Cells were transfected either with UGT1A4 common allele promoter or with promoters with single variants at -163, -217, and -219 and with
a promoter with all three variant (complete variant). Cells were then treated with 10 mM fulvestrant and luciferase activity was measured, and is
displayed as percentage difference * p value < 0.01, Δ p value ≤ 0.01.
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metabolism can influence the systemic availability and
residence time of xenobiotics, and hence affect xeno-
biotic toxicity or therapeutic effect. It is well established
that certain xenobiotics induce the expression of specific
Phase I and II metabolizing enzymes (Catania et al.
2004; Bock et al. 2000; Cummings et al. 2002). Better
understanding of simultaneous regulation of metabolism
and disposition may help to prevent these undesirable
effects. In this study, the effects of fulvestrant treatment
on the phase II enzyme UGT1A4 and the MRP family of
drug transporters in ER +MCF7 and HepG2 cells were
examined.
The high sensitivity of MCF7 and HepG2 cells towards
fulvestrant (Woode et al. 2012; Osborne et al. 2004;
Wakeling and Bowler 1987; Hu et al. 1993; Catania et al.
2004) limits time in in vitro experiments at higher doses.Figure 5 Luciferase activity in MCF7 cells +/− c-Myb transfected with
either with UGT1A4 promoter constructs containing all common alleles or U
−163, −217 and −219. Cells were treated with 10 mM fulvestrant and lucife
*p value = 0.01.In order to perform experiments at the highest effective
dose for extended times, cells were pre-treated with
1nM fulvestrant for 30 days. This allowed for the experi-
mental conditions used in this paper. Concentration and
time experiments showed that treatment with 10 nM
fulvestrant for 48 hours significantly increased UGT1A4
expression in both cell lines.
Up regulation of UGT1A4 mRNA correlates with
UGT1A4 protein expression, demonstrating that UGT1A4
protein expression is regulated at least partially by tran-
scription. In previous studies, human liver microsomes with
higher expression of UGT1A4 exhibited increased glucuro-
nidation of anastrozole (Edavana et al. 2013). To determine
if fulvestrant-induced increases of UGT1A4 expression had
a similar effect in MCF7 and HepG2 cell lines, anastrozole
glucuronidation assays were performed after fulvestrant
treatment to simulate co-treatment. UGT1A4 expressionUGT1A4 common or variant promoters. Cells were transfected
GT1A4 promoter constructs containing all variant alleles in locations
rase activity was measured, and is displayed as fold-change
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up regulation of UGT1A4 by fulvestrant has an effect on co
administration of drugs that are substrates of UGT1A4.
The increase in UGT1A4 upon fulvestrant treatment
is thought to be mediated through the ERα pathway.
When ERα was silenced in MCF7 and HepG2 cell lines,
fulvestrant treatment no longer up regulated UGT1A4
expression, confirming that the ERα pathway has a role
in UGT1A4 up regulation. There is no correlation be-
tween UGT1A4 expression and activity with ERα protein
levels; however, there is correlation with ERα mRNA, in-
dicating that there are other mechanisms or pathways
co-regulating UGT1A4 expression upon fulvestrant
treatment.
UGT1A4 promoter SNPs may also play a role in
fulvestrant-induced UGT1A4 up regulation. Glucuronida-
tion activities in different human tissues have been shown
to exhibit a high degree of variation (Edavana et al. 2013;
Shipkova et al. 2001; Strassburg et al. 2000). One explan-
ation is the presence of SNPs within the coding regions of
UGT1A4 genes that may lead to quantitative or qualitative
alterations of specific catalytic activities (Ehmer et al. 2004;
Edavana et al. 2013). Previous studies have revealed 3 SNPs
located upstream of the ATG codon at −163, -217,
and −219 (Edavana et al. 2013; Saeki et al. 2005;
Erichsen et al. 2008; Benoit-Biancamano et al. 2009).
In this study, reporter gene experiments show that
UGT1A4 transcription after fulvestrant treatment is sig-
nificantly reduced with either the −163A or the −219T
variant genotype compared to those with the com-
mon −163G or −219C genotype in MCF7 and HepG2
cell lines. In HepG2 cells, there was also a statistically
significant increase in UGT1A4 expression with the -217G
variant genotype. The genotype with all common alleles
(−163G, -217 T and -219C) appears to sustain full activity
of the UGT1A4 gene promoter fragment, but the genotype
with variant alleles reduced the activity by 40-60% in
both cells lines. Combined, these data demonstrate that
small variations in the UGT1A4 gene promoter region
alter constitutive expression of UGT1A4 upon fulves-
trant treatment. These findings may be relevant for co-
administration of drugs that areUGT1A4 substrates such
as tamoxifen, anastrozole, clozapine and lamotrigine.
Genetic variants leading to constitutive expression and
that alter the ability to respond to physiological inducers
contribute to inter-individual variability in glucuronida-
tion capacity. Therefore, pharmacogenetic risk associ-
ated with these variants should be considered in clinical
studies.
Another factor related to the up regulation of UGT1A4
by fulvestrant treatment could be through changes in the
binding capacity of transcription factors due to the pres-
ence of promoter SNPs in UGT1A4 (Quintana et al. 2011).
In silico analysis with the is-rSNP program revealed thatthe -163A variant is associated with changes in the c-Myb
transcription factor binding site (Quintana et al. 2011).
c-Myb is an oncogene that is up regulated in breast cancer
cells, and has been associated with estrogen response in
breast cancer. Silencing c-Myb in MCF7 cell lines (c-Myb
is not expressed in HepG2 cells) reduced fulvestrant in-
duced luciferase activity of the promoter with all common
alleles by 1.5 fold. There was no change in fulvestrant
induced luciferase expression in the promoter with all
variant alleles. This is the first time that c-Myb has been
reported to have a regulatory effect on the phase II me-
tabolizing gene UGT1A4.
Interplay between transporters and drug-metabolizing
enzymes has been postulated to have a major role in de-
termining a drug’s absorption and disposition (Wacher
et al. 1995; Custodio et al. 2008; Pang et al. 2009). Phase
II enzymes are localized with their transport systems,
and both are induced by the same compounds, suggesting
a correlated action (Bock et al. 2000). The transporter
genes MRP1, MRP2, and MRP3 are expressed in MCF7
cells, but only MRP2 and MRP3 are expressed in HepG2
cells (Ros et al. 2003). This study demonstrated that
fulvestrant-induced UGT1A4 expression correlated with
increased expression of MRP1 in MCF7 cells, and of
MRP2 and MRP3 in MCF7 and HepG2 cells. The present
study is the first report of UGT1A4 and MRP1, MRP2 and
MRP3 being coordinately induced by fulvestrant.
Conclusion
This data suggest that the UGT1A4-inducing activity of
fulvestrant is probably mediated by ERα, c-Myb and pro-
moter SNPs. This data also demonstrates that trans-
porter genes MRP1, MRP2 and MRP3 are also induced
by fulvestrant, suggesting they may play a role in drug
disposition in co-treatments. The clinical application of
pharmacogenomics in cancer treatment will therefore
require more detailed information concerning the func-
tional effects of genetic variants in drug metabolizing
enzymes and drug transporters.
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